Dougan, Michael

Efficacy of Tocilizumab in Patients Hospitalized with Covid-19

Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 1,362

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity

Shrock, E., Fujimura, E., Kula, T., Timms, R. T., Lee, I.-H., Leng, Y., Robinson, M. L., Sie, B. M., Li, M. Z., Chen, Y., et al. (2020) · Science

SARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing

Cited by 678

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Dougan, M., Nirula, A., Azizad, M., Mocherla, B., Gottlieb, R. L., Chen, P., Hebert, C., Perry, R., Boscia, J., Heller, B., et al. (2021) · New England Journal of Medicine

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 663

De novo design of potent and selective mimics of IL-2 and IL-15

Silva, D.-A., Yu, S., Ulge, U. Y., Spangler, J. B., Jude, K. M., Labão-Almeida, C., Ali, L. R., Quijano-Rubio, A., Ruterbusch, M., Leung, I., et al. (2019) · Nature

Protein Structure and DynamicsChemical Synthesis and Analysis

Cited by 531

Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy

Luoma, A. M., Suo, S., Williams, H. L., Sharova, T., Sullivan, K., Manos, M., Bowling, P., Hodi, F. S., Rahma, O., Sullivan, R. J., et al. (2020) · Cell

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 484

Durable antitumor responses to CD47 blockade require adaptive immune stimulation

Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences

Phagocytosis and Immune RegulationCancer Immunotherapy and Biomarkers

Cited by 366

Understanding and treating the inflammatory adverse events of cancer immunotherapy

Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 319

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H. (2019) · Trends in Immunology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 280

Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy

Qiang, L., Hoffman, M. T., Ali, L. R., Castillo, J. I., Kageler, L., Temesgen, A., Lenehan, P., Wang, S. J., Bello, E., Cardot-Ruffino, V., et al. (2023) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchTGF-β signaling in diseases

Cited by 75

Enhancing precision in detecting severe immune-related adverse events: comparative analysis of large language models and international classification of disease codes in patient records

Sun, V. H., Heemelaar, J. C., Hadzic, I., Raghu, V. K., Wu, C.-Y., Zubiri, L., Ghamari, A., LeBoeuf, N. R., Abu-Shawer, O., Kehl, K. L., et al. (2024) · Journal of Clinical Oncology

Machine Learning in HealthcareCancer Immunotherapy and Biomarkers

Cited by 38

Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control

Hughes, M. S., Zheng, H., Zubiri, L., Molina, G. E., Chen, S. T., Mooradian, M. J., Allen, I. M., Reynolds, K. L., & Dougan, M. (2019) · Cancer Medicine

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 32